Risultati per: Sviluppo di un test meno invasivo per la malattia infiammatoria intestinale

Positivo a influenza 28% dei test; presenti Covid e rhinovirus

Introduction
Cortisol is an essential stress hormone and failure of its production, known as adrenal insufficiency (AI), is associated with significant mortality due to adrenal crisis. The Short Synacthen Test (SST) is the current diagnostic test of choice for AI, but it is both invasive and resource intensive. Globally, there is an unmet need for a non-invasive, cost-effective test. A novel formulation, Nasacthin, has been developed, which can be delivered intranasally, with the resultant glucocorticoid levels measured in saliva instead of blood. The Salivary Test of Adrenal Response to Liquid Intranasal Tetracosactide (STARLIT-2) study aims to clinically validate the Nasacthin test in healthy volunteers.

Methods and analysis
STARLIT-2 is a randomised, placebo-controlled, double-blinded, four-way crossover trial. 32 healthy adults and children will be randomised to receive each of four study drugs (Synacthen, Nasacthin and their respective placebos) over four study visits (one per visit). Paired blood and saliva samples will be collected from participants at baseline, and then at 30, 60, 90 and 120 min after drug administration. Additional salivary samples will be collected at 180, 240, 360 and 480 min after drug administration. The primary outcome measures are to compare the mean serum cortisol at 30 min after Synacthen or Nasacthin dose, with a view to determine non-inferiority; and to compare the mean change from baseline in serum cortisol at 30 min after active and placebo doses of both Synacthen and Nasacthin, aiming to demonstrate superiority of active over placebo. In addition, the proportion of participants for which Nasacthin produces a rise above a preset serum cortisol threshold at 30 min will be determined, with the negative per cent agreement with the SST calculated using the SST as the reference standard.

Ethics and dissemination
The study and its amendments have been reviewed and approved by South Central–Hampshire A Research Ethics Committee. Results will be disseminated in peer-reviewed journals and conference presentations, and feedback to trial participants will be facilitated following consultation with patient and public involvement and engagement groups.

Trial registration number
ISRCTN62724177

Introduction
Helicobacter pylori is a major health problem, with the high prevalence of H. pylori and the increasing antibiotic resistance rate in China. Antibiotic resistance is the main reason for the failure of H. pylori eradication. This study aims to evaluate the efficacy and safety of susceptibility-guided quadruple therapy with antibiotic resistance using the string test coupled with quantitative PCR (qPCR) for H. pylori eradication.

Methods and analysis
This is a multicentre, open, randomised clinical trial that will enroll 324 patients with H. pylori infection. Patients will be randomised to two groups for a 14-day treatment: Treatment group will be treated with proton pump inhibitor (PPI), bismuth with two different kinds of antibiotics susceptibly guided by string test coupled with qPCR, while control group will be treated empirically with PPI, bismuth with two different kinds of antibiotics. The types and dosages of bismuth, PPI and antibiotics administered in this trial are based on the 2022 Chinese Guidelines for the treatment of H. pylori infection and the Sixth Chinese National Consensus Report on the management of H. pylori infection. The primary endpoint is the eradication rate, while secondary endpoints include compliance, the incidence of adverse events and adverse drug reactions.

Ethics and dissemination
This study was approved by the ethics committee of the Third People’s Hospital of Zhengzhou (No. 2024-04-001-K02). The results will be published in the appropriate peer-reviewed journal.

Trial registration number
ChiCTR2400082768.

Introduction
Urgent, tailored and equitable action is needed to address the alarming rise in syphilis rates in Canada. In the last decade, the rates of infectious syphilis have increased by 345% in Ontario, Canada. Underserved populations—people who use drugs, un(der)housed individuals and those living in rural and remote areas—face unique social and healthcare challenges that increase their vulnerability to syphilis infections and hinder their access to timely diagnosis and treatment. This study assesses the real-world implementation and effectiveness of using a recently approved syphilis point-of-care test in conjunction with public health outreach to break barriers and bring services to the population at the highest risk.

Methods and analysis
The Syphilis Rapid Point-of-Care Testing and Immediate Treatment Evaluation (SPRITE) study includes eight public health units in Ontario, Canada. Implementation and evaluation of this rapid ‘test and treat’ outreach model of care will be assessed using the Practical, Robust Implementation and Sustainability Model (PRISM)/Reach, Effectiveness, Adoption, Implementation, Maintenance (RE-AIM) Framework, following a community-based participatory approach. Network models will be used to estimate the population-level impact of implementing this model of care to curb transmission. Knowledge mobilisation will be assessed using the Reciprocity, Externalities, Access, and Partnership (REAP) Self-Assessment Model.

Ethics and dissemination
The SPRITE study was approved by the Queen’s University Research Ethics Board (REB) and is to be conducted in accordance with the Canadian Tri-Council Policy Statement V.2 and the latest Seoul revision of the Declaration of Helsinki. Knowledge generated from this study will be mobilised through community-based organisations and the broader public health community.

Balzanelli (Sis 118), verso una svolta epocale

Il punto dell’Iss. Il rischio internazionale resta basso

Potrebbe spiegare perché colpisce di più maschi

La Regione avvia gli accertamenti con lo ‘Spallanzani’ di Roma

La patologia di Oliviero Toscani. Cardiologi,nasce rete italiana

Si punta a risvegliare la terza serie di gemme dentali dormienti

Iniziativa EuropaColon Italia e Pierre Fabre per tutto dicembre

‘Cast’ analizza il plasma con un sistema a chemiluminescenza

Reazione autoimmune alla base della progressione della malattia

Per ora 10 su 12. Dg Tedros: ‘Ma aspettiamo altri risultati’

We read with great interest the meta’omic study by Kong et al1 which reported on metagenomic sequencing of faecal samples to discover microbiome-derived biomarkers for colorectal cancer (CRC). Faecal immunochemical test (FIT) samples provide consistent microbiome profiling based on 16S rRNA gene (ie, amplicon-based) sequencing when compared with immediately frozen samples from whole stool2 and are stable during storage for up to 20 days.3 However, it is important to understand whether FIT samples are stable for longer periods and to ascertain if metagenomic (ie, non-amplicon) sequencing is feasible using these samples, given the relatively low biomass of FIT samples compared with whole stool. Metagenomics provides better taxonomic resolution and information on functional capacity and may detect rarer taxa compared with amplicon-based sequencing.4 We aimed to (1) investigate the stability of the faecal microbiome in FIT samples that had been stored for…